Risk factors for GIST recurrence were identified , and @ risk stratification scores were developed using the database of the Scandinavian Sarcoma Group ( SSG ) XVIII trial , where @ patients with high-risk GIST with no overt metastases were randomly assigned to adjuvant imatinib @ mg/day either for @ or @ months after surgery .